Gene therapy in heart and lung disease

Current Opinion in Anaesthesiology

Volumn 17, Issue 1, 2004, Pages 13-20

  Szokol, Joseph W ^a   Murphy, Glenn S ^b   Vender, Jeffery S ^b   Nitsun, Martin ^b  

^a EVANSTON HOSPITAL   (United States)

^b NONE

Author keywords

Cystic fibrosis; Endothelial progenitor cells; Gene therapy; Gene therapy vectors; Ischemic heart disease; Lung cancer

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; DNA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; LENTIVIRUS VECTOR; LIPOSOME; MICROSPHERE; PARVOVIRUS VECTOR; POLYMER; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR ANTIGEN; VASCULOTROPIN;

ANGIOMA; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CYSTIC FIBROSIS; ENDOTHELIUM CELL; FEVER; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE REPLICATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSFECTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOST CELL; HUMAN; IMMUNE RESPONSE; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONONUCLEAR CELL; MYALGIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERIPHERAL VASCULAR DISEASE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RESTENOSIS; REVIEW; STEM CELL; SUICIDE GENE; SUICIDE GENE THERAPY; THORACOTOMY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS TRANSCRIPTION;

EID: 1342322662     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200402000-00004     Document Type: Review

References (54)

1. Kovesdi I, Brough DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997; 8:583-589.
2. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2, or E1/E4 deleted. J Virol 1998; 72:2022-2032.
3. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18:180-183.
4. Hernandez YJ, Wang J, Kearns WG, et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73:8549-8558.
5. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7:33-40.
6. Goldman MJ, Lee PS, Yang JS, et al. Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 1997; 8:2261-2268.
7. Check E. Harmful potential of viral vectors fuels doubts over gene therapy. Nature 2003; 423:573-574. A concise review of some of the potential risks of gene therapy.
8. Bragonzi A, Conese M. Non-viral approach toward gene therapy of cystic fibrosis lung disease. Curr Gene Ther 2002; 2:295-305.
9. 1 L-lactide-co-glycolide)/DNA microspheres to fascilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ther 2003; 10:1282-1288. This study describes a new and potentially useful approach in prolonging gene expression.
10. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275-288.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
12. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161:851-858.
13. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-439.
14. Isner JM, Piezek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial transfer of phVEGF 165 in patient with ischaemic limb. Lancet 1996; 348:370-374.
15. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary artery disease. Circulation 1998; 97:645-650.
16. Stegman TJ, Hoppert T, Schlurmann W, et al. First angiogenic treatment of coronary artery disease by FGF-1: long term results after 3 years. Cardiac Vasc Regen 2000; 1:1540-1544.
17. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68:830-836.
18. Fortuin FD, Vale P, Losordo DW, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003; 92:436-439.
19. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-1297.
20. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105:2012-2018.
21. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107:2677-2683. A large study of catheter-based gene transfer demonstrating safety and efficacy in patients with coronary artery disease.
22. Harvey BG, Maroni J, O'Donoghue KA, et al. Safety of local delivery of low-and medium-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13:15-63.
23. Crystal RG, Harvey BG, Wisnivesky JP, et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer to individuals with a spectrum of comorbid conditions. Hum Gene Ther 2002; 13:65-100.
24. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia. Circ Res 2002; 90:966-973.
25. Freedman SB, Vale P, Kalka C, et al. Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasma DNA. Hum Gene Ther 2002; 13:1595-1603.
26. Szmitko PE, Fedak PW, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003; 107:3090-3100.
27. Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104:2012-2017.
28. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 2002; 360:427-435.
29. Strauer BE, Brehm, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106:1913-1918.
30. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106:3009-3017.
31. 165 gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86:1198-1202.
32. Harvey BG, Leopold PL, Hackett N, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104:1245-1255.
33. Zabner J, Couture LA, Gregory RJ, et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75:207-216.
34. Hay JG, McElvaney NG, Herena J, et al. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995; 6:1487-1496.
35. Zuckermann JB, Robinson CB, McCoy KS, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10:2973-2985.
36. Reix P, Bellon G, Bienvenu J, et al. Cytokine pattern in cystic fibrosis patients during antibiotic therapy and gene therapy using adenoviral vector. Eur Cytokine Network 2002; 13:324-330.
37. Caplan NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1:39-46.
38. Gill DR, Southern KW, Mofford KA, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4:199-209.
39. Porteous DJ, Dorin JR, McLachlan G, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4:210-218.
40. Ruiz FE, Clancy JP, Perricone MA, et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001; 12:751-761.
41. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14:1079-1088. This clinical trial provides the results of the first phase I study utilizing a recombinant adeno-associated vector expressing the CFTR gene.
42. Wagner JA, Nepomuceno IB, Messner AH, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13:1349-1359.
43. Ferrari S, Kitson C, Farley R, et al. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther 2001; 8:1380-1386.
44. Zhang L, Collins PL, Boucher RC, et al. Respiratory syncytial virus (RSV) infects ciliated cells of airway epithelium via the lumenal membrane. Pediatr Pulmonol 2001; (Suppl 22):244.
45. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995; 1:890-893.
46. Sager R. Tumor suppressor genes: the puzzle and the promise. Science 1989; 246:1406-1412.
47. Swisher SG, Roth JA, Nemunaitis J et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:763-771.
48. Roth JA, Swisher SG, Merritt JA, et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998; 25:33-37.
49. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9:93-101. This phase II study demonstrated evidence of clinical efficacy after the intratumoral injection of Ad-p53.
50. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083-1092.
51. Wiewrodt R, Amin K, Kiefer M, et al. Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003; 10:353-364.
52. Tan Y, Xu M, Wang W, et al. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 1996; 16:1993-1998.
53. Tursz T, Le Cesne A, Baldeyrau P, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996; 88:1857-1863.
54. Salgia R, Lynch T, Skann A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small cell lunq carcinoma. J Clin Oncol 2003; 21:624-630.